tiprankstipranks
Trending News
More News >

Praxis Precision initiated with a Buy at Chardan

Chardan initiated coverage of Praxis Precision (PRAX) with a Buy rating and $80 price target The firm cites the potential of the company’s epilepsy franchise for the Buy rating. Praxis Precision’s lead asset ulixacaltamide recently failed the interim analysis of the Phase 3 essential tremor program, but the focus has now shifted to it epilepsy franchise, which has multiple products entering late-stage studies, the analyst tells investors in a research note.

Don’t Miss TipRanks’ Half-Year Sale

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1